Skip to main content

Heterogeneity of response to anti-TGF-β antibody therapy in preclinical models.

Wednesday, November 06, 2013 — Poster Session I

4:00 p.m. – 6:00 p.m.

FAES Academic Center (Upper-Level Terrace)




  • Y. Yang
  • J. Weng
  • M. Welsh
  • D. Weinberg
  • D. Luger
  • N. Guan
  • M. Shan
  • J. Webster
  • K.C. Flanders
  • S.M. Lonning
  • J. McPherson
  • L.M. Wakefield


TGF-βs are pleiotropic growth factors with complex roles in tumorigenesis. Overexpression of TGF-β1 in many advanced human tumors correlates with metastasis and poor prognosis, and TGF-β antagonists are being developed for cancer therapy. Using a panel of syngeneic mouse transplant models of metastatic breast cancer, we found that an anti-TGF-β neutralizing antibody suppresses metastasis in several models, including the widely-used 4T1 model. However, as expected from the complexity of TGF-β action, responses were heterogeneous and anti-TGF-β antibody treatment had no effect or even stimulated metastasis in other models. This panel of models provides a powerful platform to identify candidate biomarkers for their ability predict therapeutic response to TGF-β antibodies. Previously we have shown that therapeutic outcome does not correlate with the expression of TGF-β ligands, the growth inhibitory response of the tumor model to TGF-β in vitro, the level of Six-1 expression, or the activation of non-canonical TGF-β signaling through formation of mixed Smad complexes. We next performed extensive histopathologic and immunohistochemical characterization of the tumor models to look for features that might correlate with therapeutic response.

back to top